1 / 21

JN-International Medical Corporation

JN-International Medical Corporation. HIV RAPID IMMUNO DIAGOSTIC TEST KIT. JN-International, Inc. Product Capabilities; Lateral Flow. Test Line. Control Line. Wick. Sample. Conjugate. Negative Result. Positive Result. JN-International, Inc. HIV Two-Line Test. Wick. HIV-1 /HIV-2.

foster
Download Presentation

JN-International Medical Corporation

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. JN-International Medical Corporation HIV RAPID IMMUNO DIAGOSTIC TEST KIT

  2. JN-International, Inc.Product Capabilities; Lateral Flow Test Line Control Line Wick Sample Conjugate Negative Result Positive Result

  3. JN-International, Inc.HIV Two-Line Test Wick HIV-1/HIV-2 Control Sample Conjugate Negative Result Positive Result

  4. JN-International, Inc.HIV TRI-LINE Control HIV-2 HIV-1 Wick Sample Conjugate Negative Result Positive Result

  5. JN-QC-SPOT Rapid Tests

  6. JN-QC-SPOT Rapid HIV Test • Intended for use by properly trained personnel as a screening test for the rapid detection of antibodies to Human Immunodeficiency Virus Type 1 (HIV-1) and Type 2 (HIV-2) subtypes A-J and ‘O’ in plasma, serum, and whole blood.

  7. JN-QC-SPOT Rapid HIV Test • Hospitals • Laboratories • Medical Clinics • Physicians' offices • Emergency care situations where standard tests are not practical or available

  8. JN-QC-SPOT Rapid HIV TestProduct Goals • The ability to detect HIV-1 antibodies • The ability to detect HIV-2 antibodies • The ability to detect HIV-1, group O antibodies • Sensitivity and specificity of 98-100% • Simple and quick

  9. JN-QC-SPOT Rapid HIV Test • Sensitivity – The ability to detect positive samples • Specificity – The ability to distinguish between positive and negative samples

  10. JN-QC-SPOT Rapid HIV TestDevelopment History • Development Project began April 1996 • Configuration– November 1996 • HIV Whole Blood Format Prototype completed – September 1997 • Whole Blood Format – February 1998 • Combined Serum/plasma and Whole Blood Format – July 1998

  11. JN-QC-SPOT Rapid HIV TestClinical Trials History • First Configuration and Evaluation by Clinical Studies Conducted at - Vanderbilt Medical Center, Nashville, TN, USA - Duke University Medical Center, Durham, NC, USA. • Second Evaluation by – October 1998 • Caribbean Epidemiology Center, Pan American Health Organization, World Health Organization (WHO), Port of Spain, Trinidad • Third Evaluation by– February 1999 • Kenya Medical Research Institute, WHO East and Central Africa Reference Laboratory, Nairobi, Kenya - CONTINUED

  12. JN-QC-SPOT Rapid HIV TestClinical Trials History • Clinical Trails with Live HIV patients– January 1999 • - Martin Luther King/ Drew Medical Center, • Los Angeles, CA, USA. • Fourth Evaluation by – February 2000 • - South African National Institute of Virology, • Sandringhar, S. Africa • Fifth Evaluation by – September, 2000 • - Centro Colaborador Para El Sida (CNRS) • World Health Organization, • Buenos Aires, Argentina • Sixth Evaluation by – July, 2002 • - National AIDS Reference Laboratories (NARL) • Infectious Diseases Research Centre (IDRC) • Institute of Medical Research • Kuala Lumpur, Malaysia

  13. JN-QC-SPOT Rapid HIV TestPerforming the Assay

  14. JN-QC-SPOT Rapid HIV TestPerforming the Assay Results after 15 minutes

  15. JN-QC-SPOT Rapid HIV TestField Evaluations and Results

  16. JN-QC-SPOT Rapid HIV Test2001 Goals • Complete Validation Process • Continue with overall GMP Requirements for UK, India and Belgium • Submit clinical protocols to investigative sites • Begin clinical studies and collect data in Africa, S.Asia and S.America. • Analyze and summarize data

  17. JN-QC-SPOT Rapid HIV TestMother-to-Infant Transmission of Human Immunodeficiency Virus (HIV) The spectrum of pediatric HIV disease has changed significantly over the last few years. In recent years, the pathogenesis of vertical HIV infection has been thoroughly investigated. Findings have indicated that transmission is due to multi-factorial mechanisms, including maternal virus burden, phenotype and genotype, maternal immunologic responses, and obstetrical events during labor and delivery. Studies demonstrate that the majority of HIV vertical transmission probably occurs at the time of birth. However, perhaps one-third of cases are infected prior to delivery, and in breast-feeding populations up to 20% of infected women may transmit via nursing. Quick and early diagnosis of the HIV-infected infant is needed and possible by using rapid HIV-1&2 diagnostic test kit designed by JN-International, Inc., permitting timely and effective treatment. Advances in antiretroviral therapy, specifically the development of highly active anti-retrovirals (HAART), including combination therapies of nucleoside analogues and protease inhibitors, are also now available for children. Furthermore, more effective measures of virus burden, specially the advent of HIV RNA polymerase chain reaction (PCR) and its prognostic value for determining subsequent disease development, has changed the clinical management of HIV disease. However, this assay is time consuming and expensive, not practical for screening large number of population in the given time. Where as, rapid HIV test is advantageous for quicker screening of large population and for implementation of effective measures.

  18. Point of care testing (POCT) • Shift from central lab testing to other sites in the last decade • Diabetes monitoring • Fertility testing • Kidney and liver function • Tumor detection • Infectious disease • Alcoholoism

  19. POCT Sites • POL • Pharmacies • Wards • Emergency Room • Intensive Care • Respiratory Care • Health Screening • Long term care • Nursing Home • Homecare

  20. Point of Care Testing (POCT) 1997 WW SALES SHARE TOP VOLUME RAPID TESTS ($1-2 BB This Decade) From: The Market for Rapid InVitro Diagnostic Tests, Find/SVP, 1998

  21. JN-International Medical Corporation COMPANY:JN-International Medical Corporation is an emerging biotechnology company engaged in development and distribution of Medical Diagnostics and Vaccines for World health care and management of diseases & disorders.  The primary business objective of the corporation is participation in International Tenders for the supply of Diagnostics and Vaccines.   DIAGNOSTICS:  JN offers over 290 diagnostic products; supplying a full range of  commonly used test kits from a single source. JN's rapid tests include cardiac markers, cancer markers, sexually transmitted disease tests and infectious disease tests. JN is leading the way. In addition, our products are also used in several international epidemiological studies. JN plans to expand its product offerings and information services through its international distribution network system and the best experience for Healthcare professionals on a worldwide basis. JN products incorporate modern technology in open flexible formats that utilize genetically engineered techniques to diagnose infectious diseases and various sexually transmitted diseases, and are also used in the areas of reproductive health, viral and bacterial infectious diseases, gastrointestinal, hormones, cancer, cardiac, auto-immune disorders and for therapeutic drug treatment and drug abuse testing. JN-International Medical Corporation, P.O. Box 35,Oakland, NE 68045, USA, Tel. 402-685-6587, 402-685-6591,Fax. 402-614-4437, Omaha, NE 68122, Web site: http://www.jnii-usa-bharat.com E-mail: jninternational@msn.com

More Related